SS-31 (Elamipretide)

Mitochondria-targeted

A peptide that concentrates inside mitochondria and stabilizes the membrane where energy production actually happens.

Evidence strength: Moderate evidence. Real human data exists, with meaningful limitations. The unusual honesty here: SS-31 has real Phase II and Phase III human data, which puts it ahead of nearly everything else on this site. But those trials have repeatedly shown improvement on some measures while missing primary endpoints. Encouraging signals in primary mitochondrial myopathy, Barth syndrome, and some ophthalmic work; not a clean approval story. Well-studied and genuinely uncertain is a different thing from unstudied.

What it is

SS-31, developed clinically as elamipretide, is one of the few compounds in this space to have run large, properly controlled human trials — and one of the few whose trials produced genuinely mixed results, which is worth knowing before you read the enthusiastic coverage. It is a short peptide engineered to accumulate selectively in the inner mitochondrial membrane, where it binds a lipid called cardiolipin.

What people use it for

Mitochondrial dysfunction and primary mitochondrial disease
Age-related decline in muscle and cardiac energy production
Fatigue that appears metabolic rather than behavioral
Research contexts in heart failure and certain eye conditions

How it works

Cardiolipin is a lipid unique to the inner mitochondrial membrane, and the shape of that membrane determines how efficiently your cells produce energy. As mitochondria age or become damaged, cardiolipin degrades, the membrane loses its structure, energy output falls, and reactive oxygen species leak out. SS-31 binds cardiolipin and helps hold the architecture together — it repairs the workspace rather than pushing the machinery harder.

The technical version

SS-31 is a cell-permeable tetrapeptide with alternating aromatic and cationic residues that concentrates roughly a thousandfold in the inner mitochondrial membrane, independent of membrane potential. It binds cardiolipin, stabilizing cristae architecture and improving electron transport chain supercomplex assembly. Downstream effects include increased ATP production, reduced mitochondrial reactive oxygen species generation, decreased cytochrome c peroxidase activity, and inhibition of mitochondrial permeability transition pore opening — the latter being a key step in apoptosis.

What to realistically expect

Trial outcomes were measured over weeks to months on functional endpoints like six-minute walk distance. This is not a compound with a perceptible acute effect, and anyone reporting one is probably describing something else.

What it will not do

Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.

It will not create new mitochondria. That is biogenesis, a different process driven mostly by exercise.
It will not resolve fatigue whose cause is sleep debt, anemia, thyroid dysfunction, or depression — all of which are far more common and all of which are treatable.
It did not meet primary endpoints in several major trials, and any source presenting it as proven is not telling you the whole story.
It will not outperform zone 2 training for mitochondrial function in a healthy person.

Safety and who should be cautious

Because it went through formal clinical development, the human safety data is better than almost anything else here — generally well tolerated, with injection site reactions most commonly reported. Not FDA-approved; development has continued for specific rare indications. Anyone considering it for fatigue should have the common causes ruled out first. Not appropriate during pregnancy or breastfeeding.

Sourcing and quality

Research-grade SS-31 and clinical elamipretide are not the same supply chain. Third-party purity testing with a batch-matched certificate of analysis is the minimum, and provenance questions are fair to ask.

Questions worth asking your provider

Have we ruled out the common causes of fatigue — sleep, thyroid, iron, B12, mood?
Given that the major trials missed primary endpoints, what would we expect realistically?
What functional measure would we track to know whether anything changed?

Frequently asked questions

Is elamipretide FDA approved?

No. It has been through late-stage trials for specific rare mitochondrial conditions with mixed outcomes, and development for particular indications has continued.

Is it the same as SS-31?

Yes — elamipretide is the clinical development name for the same molecule.

Will it help general fatigue?

There is no evidence supporting that use. The studied populations had documented mitochondrial disease.

Have questions about your own situation?

General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.

Request a Consultation

Mots C Epitalon

Educational disclaimer. This page is for general education and is not medical advice. It does not diagnose, treat, or recommend any substance. Many peptides are not FDA-approved; legal status varies and some are prohibited in sport. Discuss any decision with a licensed provider.